Chronic Urticaria Disease Report
Chronic Urticaria Market: Innovation Accelerates Amid High Unmet Need and Pipeline Momentum The chronic urticaria (CU) treatment landscape is poised for disruption, with long-standing reliance on antihistamines and omalizumab giving way to a new wave of targeted therapies. Chronic spontaneous urticaria (CSU), the most common subtype, continues to present significant challenges in diagnosis and management, […]
Psoriasis Report
Psoriasis Market Outlook: Targeted Innovation Amidst Growing Competitive Pressure The psoriasis treatment landscape is evolving rapidly, with interleukin inhibitors—particularly IL-17 and IL-23 agents—driving market growth. Despite biosimilar erosion of legacy anti-TNF therapies like Humira and Stelara, the market is forecast to grow to $18.8bn by 2031 across the US, EU5, and Japan, fueled by rising […]
Sjogren’s Disease Report
Sjögren’s Syndrome: A Common, Underrecognized Autoimmune Disorder Sjögren’s disease is a chronic systemic autoimmune disorder that affects over 650,000 patients across the US, EU5, and Japan, with prevalence expected to rise to 700,000+ by 2030. Despite being one of the most common rheumatological diseases in adults, no disease-modifying therapies are currently approved in major markets. […]
